-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

Benzinga·09/25/2026 14:31:57
語音播報
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.